- Research article
- Open Access
Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells
BMC Cancer volume 15, Article number: 9 (2015)
Androgens drive the onset and progression of prostate cancer (PCa) via androgen receptor (AR) signalling. The principal treatment for PCa is androgen deprivation therapy, although the majority of patients eventually develop a lethal castrate-resistant form of the disease, where despite low serum testosterone levels AR signalling persists. Advanced PCa often has hyper-activated RAS/ERK1/2 signalling thought to be due to loss of function of key negative regulators of the pathway, the details of which are not fully understood.
We recently carried out a genome-wide study and identified a subset of 226 novel androgen-regulated genes (PLOS ONE 6:e29088, 2011). In this study we have meta-analysed this dataset with genes and pathways frequently mutated in PCa to identify androgen-responsive regulators of the RAS/ERK1/2 pathway.
We find the PTGER4 and TSPYL2 genes are up-regulated by androgen stimulation and the ADCY1, OPKR1, TRIB1, SPRY1 and PTPRR are down-regulated by androgens. Further characterisation of PTPRR protein in LNCaP cells revealed it is an early and direct target of the androgen receptor which negatively regulates the RAS/ERK1/2 pathway and reduces cell proliferation in response to androgens.
Our data suggest that loss of PTPRR in clinical PCa is one factor that might contribute to activation of the RAS/ERK1/2 pathway.
Prostate cancer (PCa) is the most commonly-diagnosed malignancy in men , and is driven by androgen hormones acting via their cognate nuclear androgen receptor (AR) transcription factor. The AR exerts its transcriptional effects by binding to DNA sequences termed androgen response elements (AREs) within promoter regions of a number of androgen-regulated genes, including genes encoding cell cycle regulators and regulators of central metabolism and biosynthesis . An important feature of PCa is prognostic heterogeneity: while some prostate cancers can remain indolent for many years others can become much more rapidly aggressive. Distinguishing key signatures between these different cancer types is a key goal. Androgen deprivation therapy (ADT) is the principal treatment for advanced PCa, although, over time, the disease becomes castration-resistant (CRPCa) with limited treatment options . Persistence of AR signalling and reprogramming of the AR transcriptional landscape may underlie progression to CRPCa [4,5], and highlights the importance of AR biology in advanced PCa. Hence, increasing our understanding of the AR signalling in PCa cells should lead to more effective treatment strategies for advanced PCa.
Recently, reciprocal cross-talk between the PI3K pathway and AR signalling has been highlighted as a potential mechanism underlying CRPCa . Alterations in PI3K signalling in advanced PCa are predominantly driven by loss of the tumour suppressor gene PTEN which contributes to the progression to invasive disease [7-9]. Another common feature of advanced PCa is hyperactivation of the RAS/ERK1/2 pathway [10-12] thought to be driven by loss of function of key negative regulators of the pathway . Although RAS/ERK1/2 activation alone cannot initiate PCa development, it can serve as a potentiating second hit to loss of PTEN to accelerate PCa progression .
Because of its established importance in clinical prostate cancer, the identification of new mechanisms through which the RAS/RAF/MAPK/ERK pathway is regulated is of great interest. We recently carried out genome-wide exon-specific profiling of PCa cells to identify novel androgen-regulated transcriptional events . As well as identifying a number of alternative mRNA isoforms , we also identified a subset of 226 novel androgen-regulated genes . In the light of evidence implicating cross-talk with AR, we searched this dataset for novel androgen-regulated genes associated with RAS/ERK1/2 signalling.
IPA Pathway analysis
Gene lists from Rajan et al.  were uploaded to the web-based Ingenuity Pathway Analysis (IPA; Ingenuity Systems) software programme, and the “Core Analysis” function was used to study direct and indirect regulatory relationships between genes and their known biological functions.
The following antibodies were used in the study: anti-PTPRR rabbit polyclonal (17937 Proteintech), anti- phospho-p44/42 MAPK mouse monoclonal (Erk1/2 Thr202/Tyr204) (Cell signalling 9106), anti-ERK2 mouse monoclonal (1647 Santa Cruz), anti-actin rabbit polyclonal (A2668, Sigma), anti-AR mouse antibody (BD Bioscience, 554226), anti-FLAG mouse monoclonal (F3165, Sigma), anti-PTEN rabbit polyclonal (Cell Signalling 138G6), anti-α-Tubulin mouse monoclonal (Sigma T5168), normal rabbit IgG (711-035-152 Jackson labs) and normal mouse IgG (715-036-150 Jackson labs). The specificity of the PTPRR antibody was confirmed by blocking with the immunising peptide (ag12145 Proteintech) (Additional file 1: Figure S2).
esiRNAs PTPRR and AR were obtained from Sigma-Aldrich (EHU078991 and EHU025951).
PTPRR cloned into pCDNA3.1 was a kind gift from Mirco Menigatti, University of Zurich. The PTPRR open reading frame was subsequently cloned into pCDNA5 using NotI and XhoI for creation of the Flp-In™-293 stable cell line.
Cell culture and androgen treatment of cells was as described previously [14,15]. All cells were grown at 37°C in 5% CO2. LNCaP cells (CRL-1740, ATCC) were maintained in RPMI-1640 with L-Glutamine (PAA Laboratories, R15-802) supplemented with 10% Fetal Bovine Serum (FBS) (PAA Laboratories, A15-101). For androgen treatment of LNCaP cells, medium was supplemented with 10% dextran charcoal stripped FBS (PAA Laboratories, A15-119) to produce a steroid-deplete medium. Following culture for 72 hours, 10 nM synthetic androgen analogue methyltrienolone (R1881) (Perkin–Elmer, NLP005005MG) was added (Androgen +) or absent (Steroid deplete) for the times indicated. Where indicated, LNCaP cells were pre-treated for 1 hour with vehicle (dimethylsulfoxide; DMSO) (Sigma, C1988) or 1 μg/ml cycloheximide (Sigma, D2438) prior to addition of 10 nM R1881 for 24 hours as previously described . Similarly, LNCaP cells were pre-treated with with 10 μM bicalutamide (Casodex, AstraZeneca) or ethanol (vehicle) for 2 hours prior to addition of 10 nM R1881 for 24 hours.
PC-3 (CRL-1435, ATCC), PC-3 M , CWR22Rv1 (CRL-2505, ATCC), DU145 (HTB-81, ATCC), and BPH-1 cells  were maintained in RPMI-1640 with L-Glutamine supplemented with 10% FBS. LNCaP-AI and LNCaP-cdxR were derived from LNCaP parental cells and maintained as previously described [19,20].
Stable LNCaP cell lines were generated by transfecting cells using Lipofectamine 2000 (11668-027, Invitrogen), followed by selection with 300 μg/ml Geneticin (Invitrogen, 10131019) (reduced to 150 μg/ml following the death of untransfected cells) for at least four weeks. Flp-In™-293 cells (R750-07, Invitrogen) were maintained in DMEM GlutaMax (Invitrogen, 10566-040), supplemented with 10% FBS (PAA Laboratories, A15-101) and stable cell lines generated using the Flp-In T-Rex Core Kit (K6500-01, Invitrogen) according to the manufacturer’s instructions. Protein expression was induced using 1 μg/ml tetracycline (T7660, Sigma) for 72 hours.
Cells were harvested and total RNA extracted using TRIzol (Invitrogen, 15596-026), according to manufacturer’s instructions. RNA was treated with DNase 1 (Ambion) and cDNA was generated by reverse transcription of 1 μg of total RNA using the Superscript VILO cDNA synthesis kit (Invitrogen, 11754-050). Quantitative PCR (qPCR) was performed in triplicate on cDNA using SYBR® Green PCR Master Mix (Invitrogen, 4309155) using Applied Biosystems 7900HT. Samples were normalised using the average of three reference genes: GAPDH, β –tubulin and actin. All primer sequences are listed in Additional file 2: Table S2.
EdU incorporation was measured over 6 hours using the Click-iT® EdU Alexa Fluor® 488 Imaging Kit (Invitrogen, C10337) and counted using ImageJ. At least 3000 cells were counted for each cell line across 3 coverslips. MTT cell proliferation assay was carried out as per the manufacturer’s instructions (Cayman, 10009365) starting with 20,000 cells per well, with 9 replicates per sample.
Six protein lysates from primary clinical prostate tumours were used in this study. Full ethical approval was obtained for human sample collection from the Northumberland, Tyne and Wear NHS Strategic Health Authority Local Research Ethics Committee (Ref: 2003/11) and written informed consent for the use of surgically obtained tissue was provided by all patients.
Genes encoding components of RAS/ERK1/2 signalling pathways are regulated by androgens in PCa cells
Complete gene lists from our ExonArray dataset  were manually curated for androgen-regulated changes within genes associated with RAS/ERK1/2 signalling. We identified potent down-regulation of SPRY1 expression in response to androgens (Log2FC = -2.37 p < 0.001). Full gene lists were then uploaded to the web-based Ingenuity Pathway Analysis (IPA; Ingenuity Systems) software programme, and the IPA ‘Core Analysis’ function was used to identify novel androgen-regulated genes within pathways associated with SPRY1 (Figure 1A & Additional file 3: Table S1). This network analysis identified a number of novel androgen-regulated genes previously linked to the RAS/RAF/MAPK/ERK signalling pathway. We confirmed androgen regulation of these genes in LNCaP cells using real-time PCR (Figure 1B). Two genes, PTGER4 and TSPYL2 were up-regulated in response to androgens, whereas five others, ADCY1, OPKR1, TRIB1, SPRY1 and PTPRR were repressed.
PTPRR is an early and direct target of the AR at the mRNA and protein level
The above network analysis suggested that the PTPRR gene is a novel androgen regulated target in the MAPK/ERK signalling network. The genomic loci of AR binding sites mapped by ChIP in LNCaP cells  were uploaded onto the UCSC genome browser. Three known AR binding sites were identified in the vicinity of the PTPRR gene, one of which was less than 5 kb upstream, and another within an internal intronic region (Additional file 4: Figure S1). To test whether the PTPRR gene might be under direct control of androgens through AR regulation, we examined PTPRR expression in LNCaP cells grown in steroid depleted medium and in cells treated with 10 nM of the synthetic androgen analogue R1881 (methytrienolone) by real-time qPCR over a 24 hour period (Figure 2A), and at the protein level over 48 hours by western blotting (Figure 2B). The specificity of the PTPRR antibody used was confirmed by peptide blocking, detection of over-expressed protein and detection of esiRNA mediated protein depletion (Figure 2B, Figure 3A and D and Additional file 1: Figure S2). PTPRR expression was rapidly reduced by 10 nM R1881 treatment at both the mRNA and protein level. Repression of the PTPRR gene and protein was also observed with a range of R1881 concentrations from 0.1 nM to 100 nM (Figure 2C). To test whether androgen-mediated suppression of PTPRR expression was a direct result of AR activity, we treated LNCaP cells with 10 nM R1881 in the presence and absence of cycloheximide to inhibit de novo protein synthesis. Androgen-mediated down-regulation of PTPRR mRNA expression was still observed in the presence of the protein synthesis inhibitor cycloheximide indicating that PTPRR repression might be directly mediated by the AR (Figure 2D). Confirming this, we found androgen-mediated PTPRR protein reduction was prevented by the AR antagonists casodex (Figure 2E), and flutamide (Figure 2F), and when cells are depleted of AR using esiRNA (Figure 2G). Immunofluorescent staining of LNCaP cells grown in the absence of androgens indicates that PTPRR protein localises to the cytoplasm (Figure 2H). The structure of the PTPRR gene and protein are illustrated in Figure 2I.
Re-expression of PTPRR in androgen treated LNCaP cells reduces phosphorylation of ERK1/2 and regulates downstream oncogenic transcription factors
The above data predicted that AR-regulated PTPRR suppression in PCa cells may contribute to modulation of RAS/ERK signaling in response to androgens. To test this prediction, we created a stable LNCaP cell line in which PTPRR was expressed under the control of the CMV promoter and a control stable cell line transfected with empty vector. This CMV promoter is active independent of androgen stimulation. In the stable cell line made with PTPRR , increased PTPRR gene expression was detected at both the RNA level (by qRT-PCR relative to three housekeeping genes) and protein level (by western analysis, relative to actin) compared to the control cell line made with empty vector (Figure 3A left and middle panels).
Consistent with stable expression of PTPRR being sufficient to dampen activity of the MAPK/ERK network, LNCaP cells over-expressing PTPRR protein also showed reduction in phosphorylated ERK1/2 in the presence of androgens (Figure 3A middle panel). As a parallel loading control, no change in total ERK1/2 levels was detected (Figure 3A right panel). Correlating with this modulation of the RAS/ERK pathway in response to PTPRR expression, we also observed parallel repression of three oncogenic transcription factors (c-fos, fra1 and c-jun) known to be downstream regulated targets of ERK1/2  (Figure 3B).
Prostate cancer cells can be genetically heterogeneous, and this can have important implications for prognosis and treatment. We recently found a synergistic effect between loss of Pten and Spry2 in murine PCa progression . To test if the ability of PTPRR to negatively regulate MAPK signalling might depend on cellular background we generated a second stable cell line over-expressing PTPRR in the HEK293 cell background which are not derived from PCa cells but are PTEN positive (Figure 3C top left panel). Consistent with an important role for cell background in the response to PTPRR expression, over-expression of PTPRR did not reduce either phosphorylation of ERK1/2 or the expression of c-fos, fra1 or c-jun in the HEK293 cell background (Figure 3C). To test whether endogenous levels of PTPRR alone were sufficient to repress phosphorylation of ERK in the absence of other signals in androgen-treated LNCaP cells, we depleted PTPRR from androgen-depleted cells. Even though over-expression of PTPRR in androgen treated LNCaP cells was sufficient to repress ERK1/2 phosphorylation, depletion of PTPRR alone by esiRNA in steroid depleted LNCaP cells was insufficient to restore ERK1/2 phosphorylation (Figure 3D). This result suggests that although PTPRR has an important role in this pathway, additional androgen-regulated proteins are involved in modulating ERK1/2 phosphorylation in response to androgens. These additional genes likely include other members of the RAS/ERK1/2 pathway (identified by our IPA pathway analysis in Figure 1).
Over-expression of PTPRR reduces LNCaP cell proliferation
The down-regulation of c-fos, fra1 and and c-jun expression in stable LNCaP cells over-expressing PTPRR suggested that androgen-mediated down-regulation of PTPRR expression might be important for proliferation of LNCaP cells. To test for such an effect on cell proliferation, we measured the proportion of cells in S-phase in our stable LNCaP cell line expressing PTPRR, and control LNCaP cells, using incorporation of EdU. Consistent with a reduced rate of proliferation, LNCaP cells over-expressing PTPRR in the presence of androgens had a reduced amount of cells in S phase over a six hour period (from 21.2% to 18.8%) relative to control cells (p < 0.04) (Figure 3E). A decrease in LNCaP cell growth in response to PTPRR expression was confirmed using an MTT assay, where there was a significant reduction in cell proliferation in PTPRR-expressing cells (p < 0.003) (Figure 3F).
Low expression of PTPRR in Invasive PCa cell lines and Clinical PCa tissue
We next examined PTPRR mRNA expression in a panel of PCa cell lines of different invasive capabilities, and with differing expression of PTEN (Figure 4A). Consistent with AR-dependent down-regulation, there was reduced PTPRR expression in the casodex resistant LNCaP derivative cell line relative to the androgen sensitive LNCaP cells (p < 0.003) (Figure 4A). Consistent with potential changes in PTPRR expression over disease progression, in these cell line models there was a low level of expression of PTPRR in PC3 cells, but expression was undetectable in their metastatic derivative PC3M.
The above data show that decreased PTPRR expression can be important to prostate cancer cell proliferation through modulation of the MAPK/ERK pathway, and this might be modulated dependent on cellular background including PTEN status. We examined PTPRR gene expression in prostate cancer clinical samples using previously published datasets that are publically available. Comparison of PTPRR expression by Affymetrix Array of 14 samples reported a 3.381 fold reduction in prostate cancer relative to normal tissue , and a 4.686 fold reduction in metastatic versus primary prostate cancer  (Figure 4B). PTPRR expression was also significantly reduced in 3 additional previously published datasets [25-27] with 2 other datasets showing no significant changes in PTPRR gene expression [11,28].
We tested PTPRR protein expression in a small panel of clinical PCa samples. Although this was a small sample set, the data suggested PTPRR has a heterogeneous expression profile in prostate tumour clinical samples. PTPRR expression was detected in half the samples but either low or undetectable in 3/6 samples (samples 3,4 and 6) despite high expression of four other control proteins (not shown). PTEN expression was also detected in 5/6 of these clinical PCa samples, but one tumour (sample 3) had low levels of both PTPRR and PTEN. Although this sample of tumours is small, these data suggest individual PCa patients have heterogeneous patterns of PTPRR expression relative to other potential modifier genes (Figure 4C, western blot with patient information shown below), and might contribute to the known heterogeneity of prostate tumours.
A common feature of aggressive PCa is hyperactivation of the RAS/ERK1/2 pathway [10,11]. ERK1/2 signalling is known to play an important role in PCa development  and activation of ERK1/2 has been correlated with malignancy [10-12]. One possible mechanism for RAS/ERK1/2 hyper-activation is loss of function of key negative regulators of the pathway, such as the Sprouty genes. SPRY1 and SPRY2 function primarily as physiological negative regulators of the RAS/ERK1/2 pathway and act to suppress prostate tumourigenesis [13,30]. SPRY1 and SPRY2 are commonly inactivated in PCa where they are linked to disease progression [22,31,32]. Using network analysis and a meta-analysis of prior exon array data, we identify concomitant down-regulation of a novel androgen-regulated gene, phosphatase receptor type R (PTPRR) as well as the known RAS/ERK1/2 pathway negative regulator SPRY1.
Here we show data to suggest that PTPRR is a direct AR target gene, and is rapidly repressed by androgens in LNCaP cells. We also demonstrate that over-expression of PTPRR in androgen stimulated cells is sufficient to decrease phosphorylation of ERK1/2 and reduce both the expression of oncogenic transcription factors and proliferation of prostate cancer cells. The PTPRR gene encodes a classical transmembrane protein-tyrosine phosphatase (PTP) receptor type R (PTPRR). PTPRR is normally expressed in the brain, placenta, small intestine, stomach, uterus and weakly in the prostate . Mouse gene Ptprr encodes multiple protein tyrosine phosphatase receptor type R (PTPRR) isoforms, which display distinct patterns of expression during neural development [34,35], and negatively regulate mitogen-activated protein kinase (MAPK) signalling pathways; both ERK1 and ERK2 are hyperphosphorylated in the brains of mice deficient for PTPRR . In cell lines PTPRR has been shown to de-phosphorylate p44/42 ERK1/2 in response to growth factors [37,38]. Repression of PTPRR expression via methylation has been detected in pre-cancerous colorectal lesions and in cervical adenocarcinoma [39,40], and in cervical cancer PTPRR may have a role in metastasis and be a biomarker of invasive cervical cancer . PTPRR expression has also recently been identified as a prognostic indicator in oral squamous cell carcinoma .
Prostate tumours show huge biological heterogeneity, with some patients living for 20 years with organ confined disease, while others progress to lethal metastatic disease within 2 years of diagnosis. A deeper understanding of this genomic diversity will help identify genomic changes which can help distinguish indolent from aggressive PCa. The RAS/ERK1/2 signalling pathway is mutated in 43% of primary PCa tumours and 90% of PCa metastases . Although PTPRR is only mutated in 1% of PCa tumours , our data demonstrates that it is a key component of the clinically important RAS/ERK1/2 signalling pathway, and that its expression level can have a clear affect on the activity of this pathway. Recent work has shown that although RAS/ERK1/2 activation alone cannot initiate PCa development, RAS/ERK1/2 and PTEN loss cooperate to promote EMT and metastasis initiated from PCa progenitor cells .
Our data also indicate that the importance of PTPRR expression on the ERK1/2 pathway activity is cell line and context dependent, suggesting cell background is important. One potential source of this cell background might be PTEN. We recently found a synergistic effect in murine PCa progression between loss of PTEN and SPRY2 . We speculate that similar to SPRY2 the effects of PTPRR on ERK1/2 signalling might only be exerted in clinical prostate cancer in the absence of PTEN (e.g. patient 3 in Figure 4C). Further in vitro and in vivo studies are required to determine whether loss of PTPRR is a consistent event in PCa, and whether reintroduction of PTPRR expression may limit the progression of CRPCa.
In summary, our study has identified the protein tyrosine phosphatase PTPRR as an early and direct target of the androgen receptor that is rapidly repressed by androgens in prostate cancer cells. Further characterisation of PTPRR protein in LNCaP cells revealed it negatively regulates the RAS/ERK1/2 pathway and reduces cell proliferation in response to androgens. Our data suggest that loss of PTPRR protein might contribute to hyper-activation of the RAS/ERK1/2 pathway and has important implications for the development of therapies targeting this pathway.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–92.
Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30:2719–33.
Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501–11.
Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell. 2013;23:35–47.
Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer. 2014;14:187–98.
Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575–86.
Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A. 1998;95:5246–50.
Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1998;95:15587–91.
Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;4:209–21.
Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 1999;59:279–84.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22.
Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012;72:1878–89.
Schutzman JL, Martin GR. Sprouty genes function in suppression of prostate tumorigenesis. Proc Natl Acad Sci U S A. 2012;109:20023–8.
Rajan P, Dalgliesh C, Carling PJ, Buist T, Zhang C, Grellscheid SN, et al. Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome. PLoS One. 2011;6:e29088.
Munkley J, Rajan P, Lafferty N, Dalgliesh C, Jackson R, Robson C, et al. A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferation. Oncotarget. 2014;5:131–9.
Frigo DE, Sherk AB, Wittmann BM, Norris JD, Wang Q, Joseph JD, et al. Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Mol Endocrinol. 2009;23:1385–96.
Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 1984;44:3522–9.
Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim. 1995;31:14–24.
Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene. 2003;22:2466–77.
Rigas AC, Robson CN, Curtin NJ. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene. 2007;26:7611–9.
Su PH, Lin YW, Huang RL, Liao YP, Lee HY, Wang HC, et al. Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer. Oncogene. 2013;32:15–26.
Patel R, Gao M, Ahmad I, Fleming J, Singh LB, Rai TS, et al. Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest. 2013;123:1157–75.
Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A. 2001;98:15149–54.
Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33:49–54.
Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001;61:7388–93.
International Genomics Consortium Expression Project for Oncology (expO) - All samples [http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2109; https://expo.intgen.org/expo/public/]
Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008;68:927–36.
Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003;63:3877–82.
Rodriguez-Berriguete G, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M. MAP Kinases and Prostate Cancer. J Signal Transduct. 2012;2012:169170.
Hanafusa H, Torii S, Yasunaga T, Nishida E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol. 2002;4:850–8.
Fritzsche S, Kenzelmann M, Hoffmann MJ, Muller M, Engers R, Grone HJ, et al. Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer. 2006;13:839–49.
McKie AB, Douglas DA, Olijslagers S, Graham J, Omar MM, Heer R, et al. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene. 2005;24:2166–74.
Augustine KA, Silbiger SM, Bucay N, Ulias L, Boynton A, Trebasky LD, et al. Protein tyrosine phosphatase (PC12, Br7, Sl) family: Expression characterization in the adult human and mouse. Anat Rec. 2000;258:221–34.
Chirivi RG, Dilaver G, van de Vorstenbosch R, Wanschers B, Schepens J, Croes H, et al. Characterization of multiple transcripts and isoforms derived from the mouse protein tyrosine phosphatase gene Ptprr. Genes Cells. 2004;9:919–33.
Van Den Maagdenberg AM, Bachner D, Schepens JT, Peters W, Fransen JA, Wieringa B, et al. The mouse Ptprr gene encodes two protein tyrosine phosphatases, PTP-SL and PTPBR7, that display distinct patterns of expression during neural development. Eur J Neurosci. 1999;11:3832–44.
Chirivi RG, Noordman YE, Van der Zee CE, Hendriks WJ. Altered MAP kinase phosphorylation and impaired motor coordination in PTPRR deficient mice. J Neurochem. 2007;101:829–40.
Blanco-Aparicio C, Torres J, Pulido R. A novel regulatory mechanism of MAP kinases activation and nuclear translocation mediated by PKA and the PTP-SL tyrosine phosphatase. J Cell Biol. 1999;147:1129–36.
Pulido R, Zuniga A, Ullrich A. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J. 1998;17:7337–50.
Menigatti M, Cattaneo E, Sabates-Bellver J, Ilinsky VV, Went P, Buffoli F, et al. The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis. Mol Cancer. 2009;8:124.
Chang CC, Huang RL, Wang HC, Liao YP, Yu MH, Lai HC. High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma. Int J Gynecol Cancer. 2014;24:201–9.
Dus-Szachniewicz K, Wozniak M, Nelke K, Gamian E, Gerber H, Ziolkowski P. Protein tyrosine phosphatase receptor R and Z1 expression are independent prognostic indicators in oral squamous cell carcinoma. Head Neck.2014; 10:1002/hed.23835.
This work was funded by Prostate Cancer UK, the J. G. W Patterson Foundation, Cancer Research UK and the Wellcome Trust (grant numbers WT080368MA and WT089225/Z/09/Z) and BBSRC (grant BB/1006923/1). The authors would like to thank Dr Stuart Williamson for providing us with the prostate tissue lysates used in this study, and Dr Mirco Menigatti for kindly providing us with the PTPRR pcDNA3.1 plasmid.
The authors declare that they have no competing interests.
JM carried out the majority of the experiments, participated in experimental design and interpretation of results, and drafted the manuscript. NPL assisted with some of the molecular experiments and was involved in the conception of the study and the interpretation of results. GK and PR carried out the IPA pathway analysis. CNR and HYL were involved in the analysis and interpretation of data, and were involved in critically revising the manuscript. DJE and PR conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
The specificity of the PTPRR antibody used was confirmed by peptide blocking with the corresponding immunising peptide.
Primer sequences used.
IPA Pathway analysis scores.
AR binding sites in ERK1/2 associated genes. Data for AR ChIP-seq peaks was uploaded from Massie et al.  supplementary data onto UCSC genome browser custom tracks. The position of AR ChIP-seq peaks detected in LNCaP cells within 100 kb of the PTPRR gene are illustrated (A). Scale bar is 100 kb. The position of AR ChIP-seq peaks detected within 100 kb of ADCY1, OPKR1, TRIB1, SPRY1, PTGER4 and TSPYL2 are shown below (B).
About this article
Cite this article
Munkley, J., Lafferty, N.P., Kalna, G. et al. Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells. BMC Cancer 15, 9 (2015). https://doi.org/10.1186/s12885-015-1012-8
- MAP Kinase
- Prostate cancer